Checkpoint Therapeutics, Inc.
checkpointtx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 13, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Aug 14, 2025.
10-Q for Q1 FY2025, filed May 13, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops immunotherapy and targeted cancer medicines for people with solid tumors, including UNLOXCYT for certain advanced squamous cell skin cancers.
10-K for FY2024, filed Mar 28, 2025
How Did They Make Money?
$41K
-
10-K for FY2024, filed Mar 28, 2025
$41K ↗
Did Revenues Turn Into Profits?
No. It lost $56.2M in FY2024.
10-K for FY2024, filed Mar 28, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2025, filed May 13, 2025
−$11.2MView ↗
- ▲ +2% (Loss)
- vs −$10.9M in Q1 FY2024
-
May 30, 2025
Sun Pharma completed its acquisition of Checkpoint
Shareholders received $4.10 in cash per share and a contingent right to a milestone payment of up to $0.70; the milestone depends on regulatory approval in Europe.
Sources
8-K, filed May 30, 2025
Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of common stock and each share of…View ↗
From trial candidate to approved treatment
The earlier report described cosibelimab as a candidate being tested; the latest report says UNLOXCYT is approved for certain advanced squamous cell skin cancers.
10-K for FY2021, filed Mar 28, 2022 10-K for FY2024, filed Mar 28, 2025We are a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel…View ↗
Collaboration rights returned
The earlier report described TG Therapeutics collaborations on assets for blood cancers; the latest says the collaborations ended and full rights reverted to Checkpoint.
10-K for FY2021, filed Mar 28, 2022 10-K for FY2024, filed Mar 28, 2025We have also entered into various collaboration agreements with TG Therapeutics, Inc. (“TGTX”), a related party, to develop and…View ↗
We initially developed cosibelimab-ipdl in solid tumor oncology indications where studies of other PD-1/PD-L1 antibodies have shown to be…View ↗
Who Did They Compete With?
Competes with Merck &, Bristol-Myers Squibb, Roche, AstraZeneca, Pfizer/Merck KGA, Regeneron, GlaxoSmithKline, Coherus, Telix Pharmaceuticals, Janssen, Novartis, Abbvie, Incyte, and Zenith Epigenetics
10-K for FY2024, filed Mar 28, 2025In the immuno-oncology area, several major pharmaceutical companies have a PD-1 and/or PD-L1 antibody on the market, including, without…View ↗
Loading...
